Company news

AlzeCure Pharma AB news in 2025

AlzeCure Pharma AB's news releases, calls and decks from 2025, newest first.

View company

AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease

December 3, 2025

AlzeCure Publishes its Interim Report for January - September 2025

November 11, 2025

AlzeCure Pharma to Present at Redeye Neurology Day on October 15

October 7, 2025

Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025

September 8, 2025

Data from AlzeCure's Pain Project ACD440 Presented at the NeuPSIG 2025 Pain Conference

September 4, 2025

AlzeCure Publishes its Interim Report for January - June 2025

August 26, 2025

AlzeCure Appoints Cecilia Wadell as New Head of Development

August 20, 2025

AlzeCure Pharma Livestreams Event about The Pain Project ACD440 and The Opportunities Within Orphan Drugs

August 19, 2025

New Scientific Data with TrkA-NAM ACD137 Against Knee Osteoarthritis to be Presented at Pain Conference

August 5, 2025

New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

July 29, 2025

AlzeCure's Rights Issue Oversubscribed, And the Company Resolves on A Directed Share Issue Under the Framework of An Overallotment Option

July 24, 2025

AlzeCure's Rights Issue Oversubscribed According to Preliminary Results

July 24, 2025

AlzeCure Presents ACD440 at the NeuPSIG 2025 Pain Conference

July 21, 2025

AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue

July 16, 2025

AlzeCure's Pain Project ACD440 Granted Orphan Drug Status in the US by the FDA

July 15, 2025

The Extraordinary General Meeting of AlzeCure Pharma AB Approved the Decision on the New Issue of Shares

July 2, 2025

AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue

June 17, 2025

Notice To Extraordinary General Meeting In Alzecure Pharma AB

June 16, 2025

AlzeCure Carries out a Rights Issue of Approximately SEK 48.5 million

June 16, 2025

AlzeCure receives positive FDA response regarding Phase II/III studies with ACD440 in a rare disease

June 12, 2025

AlzeCure Pharma to present at Redeye Investor Forum on June 11

June 4, 2025

AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on June 10

June 3, 2025

Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2025

May 14, 2025

AlzeCure Publishes its Interim Report for January - March 2025

May 5, 2025

Decks in 2025